Table of Contents Categories
  • Antidotes
  • Monoclonal antibodies
  • Boehringer Ingelheim
  • RTT
    •   Encyclosphere.org ENCYCLOREADER
      supported by EncyclosphereKSF

    Idarucizumab

    From Mdwiki - Reading time: 6 min
    Idarucizumab
    Monoclonal antibody
    TypeFab fragment
    SourceHumanized (from mouse)
    TargetDabigatran
    Names
    Trade namesPraxbind
    Other namesBI-655075
    Clinical data
    Main usesReversal of dabigatran[1]
    Side effectsHeadache, nausea, constipation[1]
    Pregnancy
    category
    • AU: B2
    Routes of
    use    		Intravenous
    Typical dose5 gram[1]
    External links
    AHFS/Drugs.comMonograph
    Legal
    License data
    Legal status
    Chemical and physical data
    FormulaC2131H3299N555O671S11
    Molar mass47782.71 g·mol−1

    Idarucizumab, sold under the brand name Praxbind, is a medication used to reverse the effects of dabigatran.[1] Specifically it is used if severe bleeding or urgent surgery is required.[1] It is given by injection into a vein.[3]

    Common side effects include headache, nausea, and constipation.[1] Severe side effects may include blood clots and allergic reactions.[1] It is a monoclonal antibody that works by binding to and inactivating dabigatran.[1][2]

    Idarucizumab was approved for medical use in the United States and Europe in 2015.[1][2] In the United Kingdom it costs the NHS about £2,400 for a dose as of 2021.[3] This amount in the United States costs about 4,500 USD.[4]

    Medical uses[edit | edit source]

    Dabigatran can be started again once 24 hours has passed from this medication being given.[3]

    Dosage[edit | edit source]

    It is given as a dose of 5 gram.[1] Occasionally a second 5 gram dose may be used.[3]

    Society and culture[edit | edit source]

    Names[edit | edit source]

    Idarucizumab is the International nonproprietary name (INN).[5] The description was updated in 2016.[6] Idarucizumab is the United States Adopted Name (USAN).[7]

    See also[edit | edit source]

    References[edit | edit source]

    1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 "Praxbind- idarucizumab injection". DailyMed. 1 December 2019. Archived from the original on 25 March 2021. Retrieved 19 August 2020.
    2. ↑ 2.0 2.1 2.2 "Praxbind EPAR". European Medicines Agency (EMA). Archived from the original on 25 October 2020. Retrieved 16 October 2020.
    3. ↑ 3.0 3.1 3.2 3.3 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 131. ISBN 978-0857114105.
    4. ↑ "Praxbind Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 2 May 2021. Retrieved 25 November 2021.
    5. ↑ World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71". WHO Drug Information. 28 (1): 90–91. hdl:10665/331151.
    6. ↑ World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76". WHO Drug Information. 30 (3): 544. hdl:10665/331020.
    7. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Idarucizumab Archived 2015-06-27 at the Wayback Machine, American Medical Association.

    External links[edit | edit source]

    External sites:
    Identifiers:
    Stub icon

    This monoclonal antibody–related article is a stub. You can help MDWiki by expanding it.

    This article is licensed under CC BY-SA 3.0.
    Original source: https://mdwiki.org/wiki/Idarucizumab
    Status: article is cached
    Encyclosphere.org EncycloReader is supported by the EncyclosphereKSF